Respiri Limited is strategically positioned to revolutionise chronic disease management globally and is focused on the US market, where RPM services qualify for Current Procedural Terminology (CPT) Code reimbursement. Respiri’s unique medical device and its Remote Patient Monitoring services empower healthcare organisations to take action from patient data when needed, not only when scheduled.
Access Telehealth, a Respiri Limited subsidiary, is reshaping chronic care management in the US through best-in-class, patient-centric, reimbursed Remote Patient Monitoring (RPM) solutions. Our clinical team and software platform enable remote care delivery to patients with chronic diseases. The company provides a seamless and timely connection between patients and healthcare providers for better, cost-effective health outcomes. Discover more at www.accessrpm.com
wheezo®, a world-first FDA-approved Class II medical device, is the sole WheezeRate detector capable of integrating into RPM programs. Developed by Respiri, wheezo® utilises innovative technology to analyse breath sounds for wheeze. The device works with the user-friendly respiri™ app, enabling users to log symptoms and triggers. The wheezo® system creates a comprehensive and individualised patient profile, fostering informed dialogues between patients and physicians.
For details on our US offerings, including wheezo®, visit www.respiri.co/us
Respiri Limited is headquartered in Melbourne with offices in New York City and Miami.
wheezo® is a registered trademark of Respiri Limited
Respiri boasts a world class team consisting of a highly respected Chief Executive Office with a career spanning the healthcare industry, providing valuable experience in medical devices, pharmaceuticals, information systems, technology and sleep disorder solutions. A General Manager of Commercial Operations leading the Commercialisation Team bringing extensive experience in health, successful launches and building teams. An experienced Chief Clinical Officer leading Respiri’s algorithm development and clinical content, and a Chief Technical Officer, with Silicon Valley pedigree, leading the build of the app and data management infrastructure.
The entire team is the driving force behind the new SaaS strategy.
Marjan has been at the helm of Respiri taking it from R&D to commercialisation since 2019. A highly experienced managing director and board member with a career spanning Australia, Europe, Japan and the US, Marjan’s focus has been in the healthcare industry; from pharmaceuticals and information services and technology to medical devices and sleep disorder solutions. He founded and subsequently sold Healthy Sleep Solutions after developing it into a successful business, with ResMed Ltd as a joint venture/shareholder partner.
Currently, Marjan also acts as commercial advisor to Portt, a SaaS company, and is an industry research fellow at University of New South Wales Faculty of Engineering.
Qualifications: BSc (Hons), University of Sydney, Grad Dip Ed, Secondary Education, University of Sydney, MCom Masters of Commerce, University of New South Wales, MAICD, Business Administration, Management and Operations, AGSM, University of New South Wales
With 27 years of experience across MedTech, HIT & Biotech start-ups/emerging growth. Brad currently, serves as CEO, President and BOD of Angel-Medical, a start-up class III implantable cardiology company. Prior to Angel-Med, he served as CEO and BOD of SonaCare Medical (Sonablate Inc.) where he successfully led an exit.
Brad has extensive experience in Sales, Marketing, Operations and fundraising with an emphasis in turnarounds including but not limited to running 3/4 commercial divisions at BTGplc (acquired by Boston Scientific for $4.2B). Previously, Brad held sales and marketing leadership positions at Medlogics, ARAGON Surgical (Acquired B Braun), Fox Hollow Technologies (Acquired $750MM) and RITA Medical (Acquired $220MM).les-Fox Hollow Tech: Acquired $1.5B
Brian is a healthcare company entrepreneur and experienced company director having co-founded six healthcare/biotechnology companies on the ASX including Oncosil Medical, Biolife Sciences (acquired by Imugene Limited in 2014) and ResApp Health (acquired by Pfizer in September 2022). He is the former director of Alcidion Limited and Chairman of Neurotech International, Nutritional Growth Solutions, NeuroScientific Biopharmaceuticals, Ausbiotech (WA) and holds a Bachelor of Economics and a Master of Business Administration from The University of Western Australia.